MET as a novel treatment target- the story of the sleeping beauty. Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine

Size: px
Start display at page:

Download "MET as a novel treatment target- the story of the sleeping beauty. Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine"

Transcription

1 MET as a novel treatment target- the story of the sleeping beauty Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine

2 MET as a novel treatment target MET as an oncogene MET in papillary renal cell carcinoma MET as a lung cancer oncogene and treatment target MET mutations MET amplification FISH testing Crizotinib experience MET exon 14 skipping Discovery Biology Actionability Acquired resistance The role of MET in acquired drug resistance Furlan et al, Ca Res 2014

3 MET as an oncogene Proto-oncogene located on chromosome 7q31.2 Activated by its ligand, HGF MET interacts directly with other signaling pathways, eg EGFR and can lead to a unique alternative activation pathway Met pathway activation Protein overexpression (transcriptional upregulation) IHC Hypoxia-mediated activation of the c-met promoter by hypoxia inducible factor 1a (HIF-1alpha) Increased HGF ligand expression Mutations DNA sequencing Gene amplification FISH Alternative splicing (exon 14 skipping) DNA sequencing Gelsomino et al, Crit Rev Hem/Onc 2014

4 MET biomarker selection by IHC- the MetMab story

5 MET targeting- initial series of failures Maroun/Rowlands, Pharm Ther, 2014

6 Papillary Renal Cell Carcinoma Germline mutations in MET present in 100% of hereditary cases of prcca Sporadic mutations in MET present in 13% of cases. PRCC accounts for 15-20% of kidney cancers MET inhibition somewhat effective- especially in hereditary type- foretinib experience

7 MET mutations in non-small cell lung cancer Kong-Beltran, Ca res 2006 Ma et al, Ca Res 2005

8 MET amplification as an actionable target? PROFILE 001 Ou et al JTO 2011 Camidge et al ASCO 2014

9 MET amplification as a better biomarker- where to draw the line? Noonan JTO 2016

10 The MET exon 14 story- Sarcomatoid lung carcinoma 1-2% of all non-small cell lung cancers with both epithelial and mesenchymal differentiation characteristics Very aggressive behavior Higher recurrence rates Resistance to standard therapy- 70% primary progression on doublet chemotherapy! Lack of understanding of genetic alterations explaining sarcoma-like features Patient s Epithelial component type 2 AD 4 AD 5 6 AD and SQC AD and SQC 16 AD 19 SQC AD 31 AD 32 AD Sarcomatou s component type Spindle and giant cells Spindle and giant cells Spindle cells Spindle cells Spindle cells Spindle cells Spindle and giant cells Spindle cells Spindle cells Mutation types 5p splice site 16bp deletion including 1 coding bp c.c2975t, p.t992i 5p intron 28bp deletion point mutation c. G3028C, p. D1010H point mutation c. G3028C, p. D1010H c.c2975t, p.t992i 5p splice site first code synonymous point mutation GAT to GAC 5p intron frameshift insertion CT insertion point mutation c. G3028C, p. D1010H Spindle and point mutation c. G3028C, p. D1010H giant cells Previous reports reported in colon cancer reported in colon cancer

11 Exon 14 skipping mutations as actionable targets in sarcomatoid lung cancer Liu et al, JCO 2016

12 Rapid and dramatic response to crizotinib in a patient with MET exon 14 skipped sarcomatoid lung cancer Nov 2014 Feb 2015

13 MET exon 14 skipping as an actionable novel oncogene Wild-type MET signaling MET exon 14 variant

14 Foundation One Frampton et al, Cancer Discov 2015 Ou et al JTO 2016

15 MSKCC experience Paik et al, Cancer Discov, 2016

16 Met exon 14 skipping- overall frequency/ overlap with amplification Awad, JCO 2016

17 Acquired drug resistance Ou et al, JTO, 2016 D1228N Heist et al, JTO, 2016

18 MET in bypass resistance Overall frequency likely around 5% Engelman Janne, Science 2007

19 Response to MET inhibitor in EGFR-mutant/METamplified case MGCD265

20 Bypass resistance

21 Acquired MET resistance- novel avenues Erlotinib- osimertinib/savolitinib Bahcall, Ca Discov 2016

22 Multiple studies assessing MET inhibition Study ID Experimental Drug Drug class Treatment Combination Phase Patient Population Biomarker Selection Targets NCT Capmatinib MET TKI Alone or with Erlotinib II Advanced EGFR-mutated NSCLC EGFRm+, MET GCN > 6 NCT Capmatinib MET TKI Cetuximab I/II Advanced Squamous Cell Carcinoma of Head and Neck, Metastatic Colorectal Cancer K-Ras/N-Ras- CRC, cmet-positive (combination of IHC and FISH) NCT Tepotinib (MSC J) MET TKI Gefitinib I/II Advanced EGFR mutation+ NSCLC, failed prior EGFR TKI EGFRm+, (ph II limited to MET IHC+, T790M-) NCT Volitinib (AZD6094) MET TKI AZD9291 I/II Advanced EGFR-mutation+ NSCLC, failed prior EGFR TKI EGFRm+ (MET+ and T790M- for ph II) NCT Cabozantinib Multi-targeted TKI Trastuzumab (if ErbB2+) II Breast Cancer, Metastatic brain disease No biomarker selection NCT Crizotinib Multi-targeted TKI Dasatinib I Diffuse Intrinsic Pontine Glioma, High-grade Glioma No biomarker selection NCT LY Anti-MET Alone or with monoclonal antibody erlotinib II Advanced EGFR-mutation+ NSCLC, failed prior EGFR TKI MET IHC+

23 Novartis: Capmatinib (INC280)

24 When to consider MET testing/targeting Advanced NSCLC Testing for MET exon 14/high level amplification should be part of multi-gene panels for ALL patients!!! NGS +/- FISH best options ctdna testing evolving Crizotinib/cabozantinib or other MET inhibitor on study an effective choice for patients- unclear at what line of treatment but should NOT be missed! EGFR-mutated NSCLC At a minimum, MET testing by FISH at time of progression for T790M- patients (ideal is to include it as part of a multigene panel) Patients should be directed towards studies of combined EGFR/MET inhibition

25 Actionable MET translocations in pediatric glioblastoma Bender, Nature Med, 2016

26 When MET met its match! Costa/Huberman, JTO

Savolitinib clinical trials June 2016 update

Savolitinib clinical trials June 2016 update Savolitinib clinical trials June 2016 update List of abbreviations BID Twice Daily MET Aberation of c-met/hgf CRC Colorectal Cancer MTD Maximum Tolerated Dose DoR Duration of Response NSCLC Non-Small Cell

More information

Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17

Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17 Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic

More information

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%

More information

Targeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute

Targeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations

More information

Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy

Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation

More information

Personalized Genetics

Personalized Genetics Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not

More information

Skipping the line: bringing MET exon 14 skipping mutations to the forefront of targeted therapy

Skipping the line: bringing MET exon 14 skipping mutations to the forefront of targeted therapy Editorial Skipping the line: bringing MET exon 14 skipping mutations to the forefront of targeted therapy Elaine Shum, Balazs Halmos Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx,

More information

Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San

Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification

More information

Disclosures Genomic testing in lung cancer

Disclosures Genomic testing in lung cancer Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing

More information

MET skipping mutation, EGFR

MET skipping mutation, EGFR New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer

More information

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon

More information

Fifteenth International Kidney Cancer Symposium

Fifteenth International Kidney Cancer Symposium The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee

More information

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018 Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as

More information

Expanding Therapeutic Options for Cancer Patients with Comprehensive Profiling Alexander Drilon MD

Expanding Therapeutic Options for Cancer Patients with Comprehensive Profiling Alexander Drilon MD Expanding Therapeutic Options for Cancer Patients with Comprehensive Profiling Alexander Drilon MD Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center COI Disclosure

More information

Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center

Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim

More information

MET exon 14 mutation: another actionable genomic variation in patients with advanced NSCLC

MET exon 14 mutation: another actionable genomic variation in patients with advanced NSCLC Commentary MET exon 14 mutation: another actionable genomic variation in patients with advanced NSCLC Massimo Di Maio 1, Paolo Bironzo 2, Giorgio Vittorio Scagliotti 2 1 Department of Oncology, University

More information

New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña

New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña Phase II GOAL TRIAL DESIGN Key inclusion criteria Patients with locally advanced or

More information

Thanyanan Reungwetwattana 1, Sai-Hong Ignatius Ou 2

Thanyanan Reungwetwattana 1, Sai-Hong Ignatius Ou 2 Commentary MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver in non-small cell lung cancer to lead MET inhibitors out of 40 years of wilderness and into a clear path

More information

Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center

Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim

More information

Molecular Testing in Lung Cancer

Molecular Testing in Lung Cancer Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans

More information

EGFR: fundamenteel en klinisch

EGFR: fundamenteel en klinisch EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation

More information

Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007

Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard

More information

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram

More information

Personalized Medicine: Lung Biopsy and Tumor

Personalized Medicine: Lung Biopsy and Tumor Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the

More information

Dr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK

Dr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer

More information

Description of Procedure or Service. Policy. Benefits Application

Description of Procedure or Service. Policy. Benefits Application Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer

More information

NSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza

NSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine

More information

The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC

The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department

More information

Integration of Genomics Into Clinical Pathways. Precision Medicine and Decision Support

Integration of Genomics Into Clinical Pathways. Precision Medicine and Decision Support Integration of Genomics Into Clinical Pathways Precision Medicine and Decision Support Faculty Andrew Hertler, MD, FACP Chief Medical Officer New Century Health Andrew Hertler, MD, FACP is employed by

More information

MECHANISMS OF 1ST GENERATION RESISTANCE. Byoung Chul Cho, M.D., Ph.D.

MECHANISMS OF 1ST GENERATION RESISTANCE. Byoung Chul Cho, M.D., Ph.D. MECHANISMS OF 1ST GENERATION RESISTANCE Byoung Chul Cho, M.D., Ph.D. CONFLICT OF INTEREST Research funding: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST Consulting role: Novartis, AstraZeneca,

More information

Lihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article

Lihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1

More information

Difficult Diagnoses and Controversial Entities in Neoplastic Lung

Difficult Diagnoses and Controversial Entities in Neoplastic Lung Difficult Diagnoses and Controversial Entities in Neoplastic Lung Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Chief, Pulmonary Pathology Service Associate Professor, Harvard

More information

D Ross Camidge, MD, PhD

D Ross Camidge, MD, PhD i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Molecular Tumor Markers for Non-Small Cell Lung Cancer (NSCLC) MP-061-MD-DE Medical Management Provider Notice Date: 10/15/2018;

More information

Drug Resistance in ALK- and ROS1-Rearranged Lung Cancers. Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017

Drug Resistance in ALK- and ROS1-Rearranged Lung Cancers. Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017 Drug Resistance in ALK- and ROS1-Rearranged Lung Cancers Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017 ALK and ROS1 are Related Tyrosine Kinases, and Both are Targeted

More information

Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~

Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ 16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of

More information

Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann

Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell

More information

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC) CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are

More information

Cell-free tumor DNA for cancer monitoring

Cell-free tumor DNA for cancer monitoring Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the

More information

Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line

Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens

More information

Other Driver Mutations: cmet, B-RAF, RET, NTRK

Other Driver Mutations: cmet, B-RAF, RET, NTRK Other Driver Mutations: cmet, B-RAF, RET, NTRK Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology and Medical Director, Memorial Cancer Institute Clinical Professor of Medicine Herbert Wertheim College

More information

Reviewers' comments: Reviewer #1 (Remarks to the Author):

Reviewers' comments: Reviewer #1 (Remarks to the Author): Reviewers' comments: Reviewer #1 (Remarks to the Author): The authors have presented data demonstrating activation of AKT as a common resistance mechanism in EGFR mutation positive, EGFR TKI resistant

More information

Molecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA

Molecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA Molecular Pathology and Lung Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA aiafrate@partners.org Disclosures Preliminary patent application NGS AMP Fusion

More information

Molecular Diagnostics in Lung Cancer

Molecular Diagnostics in Lung Cancer Molecular Diagnostics in Lung Cancer Mutations in lung carcinomas and their impact on diagnosis and treatment With special thanks to: Barbara Chaitin, MD Medical Director, Esoteric Services AmeriPath Orlando,

More information

MET in human cancer: germline and somatic mutations

MET in human cancer: germline and somatic mutations Review Article Page 1 of 6 MET in human cancer: germline and somatic mutations Elizabeth A. Tovar, Carrie R. Graveel Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, MI,

More information

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are

More information

Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS

Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS Molecular Profiling of Cancer Cells Strategies for Developing Biomarkers for Targeted Therapies of Cancer Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS Head, Department of Molecular Medicine and

More information

Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges

Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:

More information

oncogenes-and- tumour-suppressor-genes)

oncogenes-and- tumour-suppressor-genes) Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: jjchuu@mail.stust.edu.tw Genetic Basis of Cancer Cancer-causing mutations Disease of aging

More information

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University 2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling

More information

Anatomic Molecular Pathology: An Emerging Field

Anatomic Molecular Pathology: An Emerging Field Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty

More information

The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance

The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive

More information

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell

More information

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018 CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines

More information

Optimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey

Optimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer

More information

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular

More information

Transform genomic data into real-life results

Transform genomic data into real-life results CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for

More information

OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento

OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)

More information

Slide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation

Slide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology

More information

TARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide

TARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in

More information

Circulating Tumor DNA in GIST and its Implications on Treatment

Circulating Tumor DNA in GIST and its Implications on Treatment Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna

More information

Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy

Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:

More information

T790M como marcador predictivo de respuesta. Mariano Provencio

T790M como marcador predictivo de respuesta. Mariano Provencio T790M como marcador predictivo de respuesta Mariano Provencio CASO 1 Provencio et al submitted. Provencio et al submitted. C + 450 días: Progresión Taponamiento cardiaco Distress respiratorio ingreso por

More information

Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation

Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan

More information

Combined treatment with MET inhibitors and other therapies in lung cancer

Combined treatment with MET inhibitors and other therapies in lung cancer Perspective Combined treatment with MET inhibitors and other therapies in lung cancer Rakesh Bagai 1,2, Patrick C. Ma 1,2,3 1 Translational Hematology and Oncology Research, and 2 Solid Tumor Oncology,

More information

Slide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years

Slide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years Slide 1 Individualized Therapy in Lung Cancer : Where are we in 2011? Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Slide 2 Notable

More information

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,

More information

SUBJECT: GENOTYPING - EPIDERMAL GROWTH

SUBJECT: GENOTYPING - EPIDERMAL GROWTH MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature

More information

Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example

Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Targeting the Oncogenic Pathway as Opposed to the Primary Tumor Site: HER2 as an Example Dennis J Slamon, MD, PhD Professor of Medicine Chief, Division of Hematology/Oncology; Director of Clinical/Translational

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011? Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations

More information

Precision Genetic Testing in Cancer Treatment and Prognosis

Precision Genetic Testing in Cancer Treatment and Prognosis Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient

More information

Supplementary Materials for

Supplementary Materials for www.sciencetranslationalmedicine.org/cgi/content/full/3/75/75ra26/dc1 Supplementary Materials for Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Lecia V. Sequist,*

More information

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D. Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed

More information

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1 Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013

More information

Treatment of EGFR mutant advanced NSCLC

Treatment of EGFR mutant advanced NSCLC Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M

More information

Qué hemos aprendido hasta hoy? What have we learned so far?

Qué hemos aprendido hasta hoy? What have we learned so far? Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;

More information

OTRAS DIANAS MOLECULARES TRATABLES. Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña, CHUAC

OTRAS DIANAS MOLECULARES TRATABLES. Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña, CHUAC OTRAS DIANAS MOLECULARES TRATABLES Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña, CHUAC A propósito de un caso. Mujer 34 años Fumadora ocasional < 10

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer

More information

Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie

Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et

More information

Oncofocus. Patient Test Report

Oncofocus. Patient Test Report Oncofocus Patient Test Report Senior BMS: Katherine Marquis Date: 04 Apr 2016 17:01:50 PM 1 of 18 Comment: The DNA and RNA extracted from this sample were of optimal quality. The Oncofocus assay on which

More information

Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader

Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,

More information

Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications

Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Kinga Malottki, Mousumi Biswas, Jon Deeks, Richard Riley, Charles Craddock, Lucinda Billingham

More information

Comprehensive genomic profiling for various solid tumors

Comprehensive genomic profiling for various solid tumors Content Highlight Test Specification Test Content Performance Validation Test Report I II III IV V The NovoPM TM comprehensive cancer genomic profiling test Comprehensive genomic profiling for various

More information

Personalized Medicine for Advanced NSCLC in East Asia

Personalized Medicine for Advanced NSCLC in East Asia Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317 Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients

More information

EGFR ctdna Testing. Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester

EGFR ctdna Testing. Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester EGFR ctdna Testing Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester ctdna & EGFR Testing in NSCLC EGFR ctdna testing Non-invasive - patients too sick/biopsy or cytology

More information

Molecular Targets in Lung Cancer

Molecular Targets in Lung Cancer Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck

More information

Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)

Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis

More information

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome

More information

Selecting the right patients for the right trials.

Selecting the right patients for the right trials. Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug

More information

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in

More information

Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance

Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance The Oncologist Head and Neck Cancers Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance CAROLIEN BOECKX,

More information

Case Studies. Ravi Salgia, MD, PhD

Case Studies. Ravi Salgia, MD, PhD Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives

More information

Treatment of EGFR mutant advanced NSCLC

Treatment of EGFR mutant advanced NSCLC Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation

More information

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved

More information

Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance

Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance Review Article Page 1 of 15 Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance Shirin Attarian 1, Numa Rahman 2, Balazs Halmos 1 1 Department of Oncology, 2 Department

More information

MET Inhibitor. Merestinib, LY Drug Discovery Platform: Cancer Cell Signaling. Derived from Christensen JG, et al 1 ; Eder JP, et al.

MET Inhibitor. Merestinib, LY Drug Discovery Platform: Cancer Cell Signaling. Derived from Christensen JG, et al 1 ; Eder JP, et al. MET Inhibitor Merestinib, LY2801653 Derived from Christensen JG, et al 1 ; Eder JP, et al. 2 Drug Discovery Platform: Cancer Cell Signaling A Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib

More information

Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)

Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Policy Number: 2.04.143 Last Review: 1/2019 Origination: 1/2018 Next Review: 1/2020 Policy Blue Cross and Blue Shield

More information